These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22006149)

  • 1. Localized skin necrosis of steroid-induced striae distensae: an unusual complication of bevacizumab and irinotecan therapy.
    Fourcade S; Gaudy-Marqueste C; Tasei AM; Richard MA; Grob JJ
    Arch Dermatol; 2011 Oct; 147(10):1227-8. PubMed ID: 22006149
    [No Abstract]   [Full Text] [Related]  

  • 2. Ulceration of abdominal striae distensae (stretch marks) in a cancer patient.
    Dosal J; Handler MZ; Ricotti CA; Vega J; Tosti A; Kerdel FA
    Arch Dermatol; 2012 Mar; 148(3):385-90. PubMed ID: 22431783
    [No Abstract]   [Full Text] [Related]  

  • 3. Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy.
    Peters KB; Coyle TE; Vredenburgh JJ; Desjardins A; Friedman HS; Reardon DA
    J Neurooncol; 2011 Jan; 101(1):155-9. PubMed ID: 20524043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dehiscence of corticosteroid-induced abdominal striae in a 14-year-old boy treated with bevacizumab for recurrent glioblastoma.
    Wheeler H; Black J; Webb S; Shen H
    J Child Neurol; 2012 Jul; 27(7):927-9. PubMed ID: 22190499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab as secondline treatment of glioblastoma -  worth the effort?
    Rovere RK
    Klin Onkol; 2014; 27(3):219-20. PubMed ID: 24918282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ulcerations within striae distensae associated with bevacizumab therapy.
    Farber SA; Samimi S; Rosenbach M
    J Am Acad Dermatol; 2015 Jan; 72(1):e33-5. PubMed ID: 25497948
    [No Abstract]   [Full Text] [Related]  

  • 7. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
    Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
    Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localized skin necrosis by bevacizumab.
    Frances L; Guijarro J; del Carmen Leiva-Salinas M; Albares MP; Ramon R
    Eur J Dermatol; 2013 Apr; 23(2):251-2. PubMed ID: 23568603
    [No Abstract]   [Full Text] [Related]  

  • 9. [Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
    Laigle-Donadey F; Dehais C; Mazeron JJ; Sanson M
    Bull Cancer; 2009 Mar; 96(3):291-7. PubMed ID: 19318307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan and bevacizumab in recurrent glioblastoma multiforme.
    Jakobsen JN; Hasselbalch B; Stockhausen MT; Lassen U; Poulsen HS
    Expert Opin Pharmacother; 2011 Apr; 12(5):825-33. PubMed ID: 21385110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [An evaluation of fatigue in patients with glioblastoma relapse treated with the combination of irinotecan-bevacizumab].
    Dehais C; Souvannavong V; Nguyen BK; Jouniaux-Delbez N; Golmard JL; Tadrist C; Liou A; Delattre JY
    Rev Neurol (Paris); 2011 Nov; 167(11):841-6. PubMed ID: 21514945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab plus irinotecan in recurrent glioblastoma.
    Chamberlain MC
    J Clin Oncol; 2008 Feb; 26(6):1012-3; author reply 1013. PubMed ID: 18281677
    [No Abstract]   [Full Text] [Related]  

  • 13. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
    Zhang G; Huang S; Wang Z
    J Clin Neurosci; 2012 Dec; 19(12):1636-40. PubMed ID: 23047061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topoisomerase I inhibitors for the treatment of brain tumors.
    Feun L; Savaraj N
    Expert Rev Anticancer Ther; 2008 May; 8(5):707-16. PubMed ID: 18471044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
    Narita Y
    Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical diltiazem for ulceration of striae distensae associated with bevacizumab therapy.
    Fuentes RC; Wittel JB; Paez PS; Vayo CA; Mir JC
    Dermatol Ther; 2019 Jan; 32(1):e12750. PubMed ID: 30238587
    [No Abstract]   [Full Text] [Related]  

  • 17. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
    Friedman HS; Prados MD; Wen PY; Mikkelsen T; Schiff D; Abrey LE; Yung WK; Paleologos N; Nicholas MK; Jensen R; Vredenburgh J; Huang J; Zheng M; Cloughesy T
    J Clin Oncol; 2009 Oct; 27(28):4733-40. PubMed ID: 19720927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.
    Khasraw M; Ameratunga M; Grommes C
    Expert Opin Biol Ther; 2014 May; 14(5):729-40. PubMed ID: 24655021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.
    Fellah S; Girard N; Chinot O; Cozzone PJ; Callot V
    J Clin Oncol; 2011 Apr; 29(11):e308-11. PubMed ID: 21263101
    [No Abstract]   [Full Text] [Related]  

  • 20. [Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
    Vauleon E; Mesbah H; Gedouin D; Lecouillard I; Louvel G; Hamlat A; Riffaud L; Carsin B; Quillien V; Audrain O; Lesimple T
    Bull Cancer; 2012 Feb; 99(2):121-6. PubMed ID: 22257744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.